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Abstract
Background: Testosterone (T) induces a rapid relaxation in vascular tissues of
different species due to a nongenomic effect of this steroid on vessels. Different
mechanisms have been proposed to explain T-induced vasodilatation but the
effective mechanism(s) and the mediators involved are still a matter of debate.
Objectives: We have evaluated if H2S pathway is involved in T vascular effects.
Design and setting: MaleWistar rats were sacriﬁced and thoracic aortawas rapidly
dissected and cleaned from fat and connective tissue. Rings of 2–3 mm length were
cut and placed in organ baths ﬁlled with oxygenated Krebs solution at 37 8C and
mounted to isometric force transducers. H2S determination was performed on
thoracic aortic rings incubated with T or vehicle and in presence of inhibitors. H2S
concentration was calculated against a calibration curve of NaHS (3–250 mM).
Results were expressed as nmoles/mg protein.
Measurements: Vascular reactivity was evaluated by using isometric transducers.
H2S determinationwas performed by using a cystathionine b-synthetase (CBS) and
cystathionine g lyase (CSE) activity assay. CSE and CBS protein levels were assessed
by Western blot analysis. Statistical analysis was performed by using two-way
ANOVA and unpaired Student’s t-test where appropriate.
Results: T signiﬁcantly increased conversion of L-cysteine to H2S. This effect was
signiﬁcantly reduced by PGG and BCA, two speciﬁc inhibitors of CSE. T (10 nM–
10 mM) induced a concentration-dependent vasodilatation of rat aortic rings in
vitro that was signiﬁcantly and concentration-dependent inhibited by PGG, BCA,
and glybenclamide. Incubation of aorta with T up to 1 h did not change CBS/CSE
expression, suggesting that T modulates enzymatic activity.
Conclusions: Here we demonstrate that T vasodilator effect involves H2S, a novel
gaseous mediator. T modulates H2S levels by increasing the enzymatic conversion
of L-cysteine to H2S.
# 2008 European Association of Urology. Published by Elsevier B.V. All rights reserved.
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In the last two decades, growing epidemiologic, clinical, and
experimental evidence have shown a marked sexual
dimorphism in cardiovascular function and in the patho-
genesis of cardiovascular disease. Numerous studies have
correlated reduced circulating levels of testosterone to
severe coronary artery disease (CAD) [1], atherosclerotic
risk [2,3], and other pathologies, including hypertension,
diabetes and insulinaemia [4], implicating a possible
beneficial effect of testosterone on the cardiovascular
system. In addition, it has been reported that chronic
testosterone treatment reduces serum levels of IL-1 beta,
TNF alpha, and increases the levels of the anti-inflammatory
cytokine IL-10 [5,6], conferring to this hormone long lasting
cardiovascular benefits. Several studies have shown that
acute administration of testosterone induces a rapid
relaxation in vascular tissues of different species including
humans [8–11], suggesting a nongenomic effect of this
hormone on vascular reactivity. Different mechanisms have
been proposed to explain testosterone-induced vasodilata-
tion [7,8,12] but it remains a matter of debate which is the
effective mechanism(s) and which are the mediators
involved of the testosterone-induced vasorelaxation.
Hydrogen sulphide (H2S) is an endogenous gas produced
in mammals from L-cysteine by two different enzymes:
cystathionine b-synthetase (CBS), predominantly present in
central nervous system (CNS), and cystathionine g-lyase
(CSE), predominantly localised in the cardiovascular net-
work [13–15]. Recently, H2S has been shown to act as
gaseous modulator on rat vascular system both in vivo [16]
and in vitro [17]. Some studies have suggested that
testosterone-induced vasodilatationmay involve activation
of vascular smooth muscle potassium channels [18,19]. The
finding that activation of potassium channels is involved in
testosterone-induced vasodilatation led us to hypothesize a
possible involvement of H2S as a mediator involved, since
drugs that block KATP channels, such as glibenclamide, have
been shown to block the relaxant effect caused by
exogenous H2S [20,21]. Here, we have evaluated the
possible involvement of H2S in the vasorelaxant effect of
testosterone by using rat isolated aorta.
2. Materials and methods
2.1. Materials
Acetylcholine (ACh), L-phenylephrine (PE), tetraethylammonium
(TEA), testosterone (T), polyethylene glycol 400 (PEG), dimethyl
sulfoxide (DMSO), propargylglycine (PGG), b-cyano-L-alanine (BCA),
N,N-dimethylphenylenediamine sulphate (DPD), pyridoxal-50-phos-
phate hydrate (PP), iron chloride (FeCl3), zinc acetate (ZnAc), NaHS, L-
cysteine, and glybenclamide (gly) were purchased from Sigma
Chemical Co (Milan, Italy). Trichloroacetic acid (TCA) was purchased
from Carlo Erba Reagents (Milan, Italy). Dulbecco’s modiﬁed Eagle
medium (DMEM), L-glutamine, penicillin, and streptomycin were
purchased from Hy-Clone (Road Logan, UT, USA). Testosterone was
dissolved in PEG, glybenclamide in DMSO, TEA and PGG in dH2O. The
volume added to the organ bath for each compound was 2.5 ml, except
for TEA, which was 25 ml.2.2. Tissue preparation
Male Wistar rats (Charles River, 250–300 g) were sacriﬁced and thoracic
aorta was rapidly dissected and cleaned from fat and connective tissue.
Rings of 2–3 mm lengthwere cut and placed in organ baths (2.5 ml) ﬁlled
with oxygenated (95%O2–5%CO2) Krebs solution at 37 8C andmounted to
isometric force transducers (type 7006, Ugo Basile, Comerio, Italy) and
connected to a Graphtec linearcorder (WR3310, Japan). The composition
of the Krebs solution was as follows: (mM): NaCl 118, KCl 4.7, MgCl2 1.2,
KH2PO4 1.2, CaCl2 2.5, NaHCO3 25, and glucose 10.1. Rings were initially
stretched until a resting tension of 0.5 g was reached and allowed to
equilibrate for at least 30 min, during which tension was adjusted, when
necessary, to 0.5 g and bathing solution was periodically changed. In a
preliminary study, a resting tension of 0.5 g was found to develop the
optimal tension to stimulationwith contracting agents. The studies were
carried out in accordance with the Declaration of Helsinki of the
European Community guidelines for the use of experimental animals.
2.3. Experimental protocol
In each experiment, rings were ﬁrst challenged with PE (1 mM) until the
responses were reproducible. In order to verify the integrity of the
endothelium, Ach cumulative concentration-response curve (10 nM–
30 mM) was performed on PE-precontracted rings. The rings were then
washed and contracted with PE (1 mM) and, once a plateau was reached,
a cumulative concentration-response curve of testosterone (10 nM–
10 mM) performed. In another set of experiments, rings were contracted
with KCl (60 mM) and a cumulative concentration-response curve of
testosterone (10 nM–10 mM) performed.
2.4. Drug treatments
The optimal incubation time of the drug treatments and concentration
were selected from literature as speciﬁed for each protocol below
reported. The experimental protocols were:(1) TEA (10 mM) [22] and Glybenclamide (10, 50 mM) [20] were added
in the organ baths. After 60 and 30 min, respectively, the rings were
contracted with PE (1 mM) and a cumulative concentration-response
curve of T was performed.(2) PGG and BCA [23,24] (1, 3, 10 mM) were added in the organ baths,
after 15 and 60 min respectively, rings were contracted with PE
(1 mM) and cumulative concentration response-curve of T was
performed.(3) Rings were contracted with KCl 60 mM, once plateau was reached
cumulative concentration-response curve of T was performed.
Drug addition and incubation time selected did not alter the
contraction induced by PE (data not shown).
2.5. CSE/CBS activity assay
H2S determination was performed according to Stipanuk and Beck [25]
with modiﬁcations. Brieﬂy, the thoracic aorta was dissected, placed in
sterile phosphate buffer solution, and cleaned of fat and connective
tissue. Rings, of the same size as described above, were cut and placed in
24 plate with 990 ml Krebs solution for 30 min at 37 8C in an incubator
(Mod. BB6220, Heraeus Instruments, Germany) with humidiﬁed air (5%
CO2/95% O2). After this time, T (10 mM) or vehicle (PEG; 10 ml) was added
and the rings were incubated for 5, 15, 30, and 60 min. In another set of
experiments, aortic rings were exposed to PGG or BCA (10 mM) for 15
and 60 min respectively, then testosterone (10 mM) or vehicle were
added for 30 and 60 min. At the end of the incubation time, the aortic
Fig. 1 – Time course of L-cysteine-stimulated H2S production in rat aorta
following incubation with T (10 mM) for 5, 15, 30, and 60 min. Control
value (vehicle) of H2S production was 153W 23 nmoles/mg protein. n = 4,
* = p < 0.05, ** = p < 0.01 vs vehicle. Data are expressed as fold increase
compared to vehicle.
Fig. 2 – PGG and BCA (10 mM) inhibited testosterone-induced H2S
biosynthesis in rat aorta. V = vehicle (dH2O), T = testosterone, PGG and
BCA. ** = p < 0.01 vs C, 8 = p < 0.05 vs V. Data are expressed as fold increase
of H2S production n = 4.
E U RO P E AN URO LOGY 5 6 ( 2 0 0 9 ) 3 7 8 – 3 8 4380rings were homogenized in a lysis buffer (potassium phosphate buffer
100 mM pH = 7.4, sodium orthovanadate 10 mM and protease inhibitor)
and the protein concentration was determined using Bradford assay
(Bio-Rad Laboratories, Milan, Italy). The homogenates were added in a
reaction mixture (total volume 500 ml) containing piridoxal-50-phos-
phate (2 mM, 20 ml), L-Cysteine (10 mM, 20 ml), and saline (30 ml). The
reaction was performed in paraﬁlmed eppendorf tubes and initiated by
transferring tubes from ice to a water bath at 37 8C. After incubation of
30 min, ZnAc (1%, 250 ml) was added to trap evolved H2S followed by TCA
(10%, 250 ml). Subsequently, DPD (20 mM, 133 ml) in 7.2M HCl and FeCl3
(30 mM, 133 ml) in 1.2M HCl were added. After 20 min, absorbance
values were measured at a wavelength of 650 nm. All samples were
assayed in duplicate and H2S concentration was calculated against a
calibration curve of NaHS (3.12–250 mM). Results were expressed as
nmoles/mg of protein.
2.6. Western blotting
The thoracic aorta was dissected, placed in sterile phosphate buffer
solution, and cleaned of fat and connective tissue. Rings, of the same size
as described above, were cut and placed in 24 plate with 990 ml DMEM
solution (containing penicillin 100 U ml1, streptomycin 100 mg ml1,
and L-glutamine 2 mM) for 30 min at 37 8C in an incubator (Mod.
BB6220, Heraeus Instruments, Germany) with humidiﬁed air (5% CO2/
95% O2). After this time, T (10 mM) or vehicle (PEG; 10 ml) was added and
the rings were incubated for 15, 30 min, and 1 h. At the end of the
incubation time, the aortic rings were homogenized on ice in the
following lysis buffer: Tris-HCl 50 mM pH 7.4, NP-40 1%, Na-
deoxycholate 0.25%, NaCl 150 mM, EDTA 1 mM, PMSF 1 mM, Aprotinin,
leupeptin, 1 mg/ml each, Na3VO4 1 mM, NaF 1, and mM. After
centrifugation at 12,000 rpm for 15 min, protein concentration was
determined by Bradford assay using BSA as standard (Bio-Rad
Laboratories, Milan, Italy). 30 mg of the denatured proteins were
separated on 10% sodium dodecyl sulphate polyacrylamide gel and
transferred onto a PVDF membrane (Millipore). Membranes were
blocked by incubation in PBS containing 0.1%v/v Tween-20 and 5%
nonfat dry milk for 1 h at room temperature, and then incubated with
mouse anti-CBS polyclonal antibody (1:1000, Novus Biological) and
mouse anti-CSE monoclonal antibody (1:500, Novus Biological) over-
night at 4 8C. Themembraneswerewashed extensively in PBS containing
0.1% v/v Tween-20 and then incubated with the secondary antibody
(1:5000) conjugated with horseradish peroxidase, antimouse IgG for 2 h
at 4 8C. The ﬁlters were then washed and the immoreactive bands were
visualised using the enhanced chemiluminescence substrate (ECL,
Amersham Pharmacia Biotech).
2.7. Statistical analysis
All data were expressed as mean  SE mean. Statistical analysis was
performed by using two-way ANOVA and unpaired Student t-test where
appropriate. Differences were considered statistically signiﬁcant when p
was less than 0.05.
3. Results
In order to evaluate if testosterone could modulate H2S
production, we measured its effect on aorta following
incubation with the vehicle or L-cysteine. Incubation of
aortic rings with vehicle, eg, the basal levels of H2S
production,were unaffected by testosterone exposure, while
the conversion of L-cysteine in H2S was enhanced in tissues
exposed to testosterone (Fig. 1). Indeed, incubation of aortic
rings with testosterone at the concentration of 10 mM for 5,15, 30, or 60 min significantly increasedH2S production after
30 and 60 min (Fig. 1). Meanwhile, the incubation for 5 and
15 min did not modify the production of H2S (Fig. 1).
Propargylglycine (PGG) and b-cyano-L-alanine (BCA), two
inhibitors of CSE, significantly reduced T-induced H2S
production (Fig. 2), supporting the hypothesis that testos-
terone positivelymodulates L-cysteine-induced H2S produc-
tion through a direct action on CSE. To further address the
involvement of H2S in the testosterone-induced vasorelaxa-
tion,weperformedan in vitro functional study using BCAand
PGG in order to perform a pharmacologic modulation. Both
PGG (Fig. 3b) and BCA (Fig. 3c) inhibited testosterone-
induced vasorelaxation and this effect was concentration-
dependent. These data confirmed that testosterone mod-
ulates H2S release through CSE. Following this latter finding,
weperformedaWesternblot analysis toevaluate if therewas
achange inproteinexpressionofeitherCBSorCSE.The lackof
change in protein expression (Fig. 4), within the time frame
considered in this study, suggests that testosterone aug-
mented H2S synthesis by increasing enzyme activity rather
Fig. 3 – Cumulative concentration-response curve of T on rat aortic rings.
*** = p < 0.001, n = 7 (panel A). Incubation with PGG (panel B), or BCA
(panel C), at different concentrations, of rat aorta rings inhibited
T-induced vasodilatation. ***p < 0.001, *p < 0.05, n = 6 for each set of
experiments.
Fig. 4 – Testosterone incubation of rat aorta did not change CBS or CSE
expression. Panel A shows a representative Western blot for CBS and CSE.
Panels B and C show Western blot densitometric analysis densitometry
for CBS and CSE, respectively (n = 3 experiments).
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experimental conditions potassium channels are involved
in testosterone-induced vasorelaxation (Fig. 5). The testos-
terone cumulative concentration response curve was sig-
nificantly inhibited when rings were contracted with KCl
(Fig. 5a) or in presence of TEA (Fig. 5b) as opposite to PE
(Fig. 5a) implying the involvement of potassium channels.
Incubation of aortic ringswithGly, a specific inhibitor of KATP
channels, concentration-dependently inhibited testoster-
one-induced vasorelaxation, confirming that T exerts its
effect, in our experimental conditions, mainly through KATP
channels (Fig. 5c).
4. Discussion
Hydrogen sulphide is a gaseous mediator that has been
shown to play a role in the cardiovascular system. It has
been hypothesised that one of the mechanisms involved inits action is activation of KATP channels [26]. Since KATP
channels have been shown to be involved in testosterone
effects [20,21] we evaluated if H2S is involved downstream
in testosterone signalling. We first verified the involvement
of H2S in testosterone-induced vasodilatation by operating
a pharmacologic modulation. Incubation of aorta rings with
PGG or BCA, two different CSE inhibitors of L-cys/H2S
pathway, led to a significant and concentration-dependent
inhibition of testosterone-induced vasodilatation. These
data imply that H2S can play a role as downstream signal in
the vasodilatory effect of testosterone, but they did not
represent a direct proof that testosterone can cause H2S
release and/or generation. In order to address this issue, we
evaluated if incubation of aorta tissue with testosterone
could induce H2S production and/or increase the conversion
of the substrate L-cysteine to H2S. In the aorta homogenate
following incubation with testosterone, there was no
detectable increase in the basal release of H2S. Conversely,
when homogenate was challenged with L-cysteine, there
was a significant increase of H2S production after 30 and
60 min of incubation. The finding that H2S levels after 5 and
15 min were not different seems to be an apparent
discrepancy with functional data where the concentra-
tion-response curve of testosterone lasts 10–30 min. This
Fig. 5 – Panel A: Effect of testosterone on KCl (60 mM) pre-contracted rings;
panel B: effect of TEA (10mM); and panel C: effect of glybenclamide
(10, 50 mM) on testosterone-induced vasorelaxation. *** p < 0.001,
** = p < 0.01, * = p < 0.05, n = 6 for each group.
E U RO P E AN URO LOGY 5 6 ( 2 0 0 9 ) 3 7 8 – 3 8 4382apparent discrepancy reflects the limit of the assay, whose
lower limit is 3 mM. In other words, most likely the
concentration of H2S necessary to obtain the effect in vitro
in the functional experiments is out of the detection limit of
the assay. The finding that T incubation did not enhance the
basal release of H2S but significantly enhanced L-cysteine-
stimulated production of H2S suggested a possible positive
modulation of CSE/CBS activity by testosterone rather than
an increase in enzyme expressions. To explore this issue, we
performed the in vitro assay in the presence of either PGG or
BCA. Both BCA and PGG significantly inhibited T-induced
H2S production. Interestingly, both inhibitors reversed H2S
levels to the control value, further suggesting that
testosterone effect is on the enzyme activity rather than
on the enzyme expressions. This last hypothesis was
confirmed by the Western blot analysis performed on
tissues exposed to testosterone where the expression of
either CBS or CSE was not modified. Thus, in ourexperimental conditions and in the early time frame
considered in our study, testosterone increases CSE/CBS
activity rather than their relative expression.
Having determined a role for H2S in testosterone-
induced vasodilatation, we addressed the other point we
aimed to confirm: the involvement of KATP channels in our
experimental conditions. Indeed, H2S activity has been
linked to potassium channels activation and in particular to
KATP channels [20,26–28]. We first addressed the possible
involvement of potassium conductance, comparing testos-
terone cumulative concentration-response curve following
contraction with either KCl or PE. When rings were
contracted using the depolarizing effect of KCl, testoster-
one-induced vasodilatation was abrogated, indicating the
involvement of potassium conductance. This finding is in
line with the literature, where it has been clearly shown
that calcium-activated and/or large conductance calcium-
activated K+ channels are involved in testosterone-induced
vasorelaxation [10,12,29]. This finding was further sup-
ported by the finding that TEA significantly inhibited
testosterone-induced vasorelaxation. However, since TEA
is known to block different types of K+ channels [22] we
used glybenclamide, a specific inhibitor of K+ATP channels.
Glybenclamide inhibited testosterone vasodilator action in
a concentration-dependent manner, confirming that KATP
channels are the major player in our experimental
conditions. Thus, testosterone-induced vasorelaxation
involves H2S biosynthesis that in turn activates KATP
channels.
5. Conclusions
Several studies have shown that acute administration of
testosterone induces a rapid relaxation in vascular tissues of
different species, including humans, suggesting a nonge-
nomic effect of this hormone on vascular reactivity.
Different mechanisms have been proposed to explain
testosterone-induced vasodilatation, but is the effective
mechanism(s) and themediators are a still matter of debate.
Here we have shown that the testosterone nongenomic
vascular effect involves the L-cysteine/H2S pathway. In
particular, the data presented demonstrate that, in rat aorta,
the nongenomic effect of testosterone is linked to a positive
modulation of CSE/CBS activity. The H2S produced acts on
KATP channels, contributing to the vasodilator effect of
testosterone. Thus, H2S involvement in the vascular activity
of testosterone may help to explain the beneficial effects of
testosterone on the cardiovascular system.
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2004;107:149–58.The ‘‘love story’’ between testosterone and sexual
medicine began several years ago. Suddenly, the
‘‘revolutionary blue pill’’ arrived, and we had the
probably erroneous presumption to potentially treat
or cure each patient using the same oral compound. It
was not to be: phosphodiesterase type 5 inhibitors
(PDE5-Is) by themselves are not always a ‘‘magic’’
cure [1].
In this scenario, based on the preclinical and clinical
data available in the literature to date, it is possible to infer
that androgens are essential for the development and
growth of the penis, and they play a critical role in
maintaining erectile physiology in men [2,3]. On the basis
of the evidence derived from laboratory animal studies
and the most up-to-date clinical data, it has been
postulated that an androgen insufficiency may disrupt
cellular signalling pathways and produce pathologic
alterations in penile tissue, finally leading to erectile
dysfunction (ED) [3]. Vascular physiology and penile
haemodynamics—namely the functional properties of the
penile tissue throughout the erection process—certainly
deserve an adequate androgen milieu. In this context,
circulating testosterone has been proven to have a
nongenomic effect towards vascular reactivity, promoting
a rapid relaxation of the vascular beds.
How does testosterone have this effect? Different
mechanisms have been proposed [4,5]. The present study
by Bucci et al [6] elegantly suggests that testosterone
might increase the overall production of hydrogen
sulphide, a gaseous modulator with affinity for, at least,
the rat vascular system, both in vivo and in vitro. But even
the famous nitric oxide (NO) is a gas, isn’t it? Do you
remember the functional pathway for sildenafil and
similar drugs? It certainly deserves the activation of the
NO–cyclic guanosine monophosphate (cGMP) pathway to
properly work, thus promoting a penile erection [7].
Therefore, from a clinical standpoint, it is important to
once more highlight that screening for hypogonadism in
men with ED is certainly necessary to identify those with
an inadequate circulating testosterone level who may
benefit from testosterone substitution [1,8]. Identification
of threshold values for testosterone supplementation has
been rigorously reported [8], and convincing data has
shown who should actually be appropriately treated with
a combined therapy when PDE5-Is alone fail.
Fortunately, research in sexual medicine can still move
forward!
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